Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease
Status:
Terminated
Trial end date:
2016-12-14
Target enrollment:
Participant gender:
Summary
Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion
and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to
assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the
subjects were followed up as out-patients during 5 study visits for 12 months in total.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bioinova, s.r.o.
Collaborator:
Department of Spine Surgery, University Hospital Motol, Prague, Czech Republilc